<DOC>
	<DOCNO>NCT00703755</DOCNO>
	<brief_summary>The purpose study study effect different combination fenofibrate metformin cluster metabolic syndrome ( MetS ) biochemical abnormality , determine dose combination allow normalization MetS patient .</brief_summary>
	<brief_title>A Randomized , Double-Blind Trial Comparing Efficacy Safety Fenofibrate , Metformin , Their Combination Placebo Patients With Metabolic Syndrome .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Male female patient age 18 75 year old ( inclusion V1 ) . With 3 follow 5 criterion , include least 2 biochemical abnormality ( glucose one lipid abnormality ) And sign write inform consent ( inclusion V1 ) . know Type 1 diabetes , treat type 2 diabetes [ 25 ] , [ 26 ] ; wth HbA1c &gt; 8 % [ 27 ] first blood sample ; body mass index ( BMI ) &gt; 45 kg/m2 ; female surgically sterilize use adequate contraceptive use adequate contraceptive precaution postmenopausal pregnant lactating woman ; know hypersensitivity fibrates ; know hypersensitivity metformin chlorhydrate ; know abnormal thyroid hormone level , high thyroid stimulate hormone ( TSH ) level ; receive investigational drug last 30 day date randomization ; unable unwilling comply protocol ; likely withdraw study completion ; treat concomitant medication : reporting change within last 6 week randomization study medication could interfere lipid profile ( i.e. , antihypertensive drug , oral corticosteroid , thyroid hormone , retinoids , thiazidic derivative , hormone replacement therapy ) ; present follow disease condition : chronic respiratory insufficiency , patient medical device sleep apnea ; current chronic pancreatitis , identify risk know history acute pancreatitis ; hepatic insufficiency , acute alcohol intoxication , alcoholism ; know cholelithiasis without cholecystectomy ; aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2 time upper limit normal ( ULN ) ; musculoskeletal disease increase creatine phosphokinase ( CPK ) &gt; 3 time ULN ; renal failure renal dysfunction define serum creatinine level &gt; 135 μmol/L male &gt; 110 μmol/L female [ 28 ] ; acute condition potential alter renal function dehydration , severe infection , shock intravascular administration iodinate contrast agent ; acute chronic disease may cause tissue hypoxia cardiac respiratory failure , recent myocardial infarction ( within 3 month prior randomization ) , shock ; know gastric peptic ulcer intestinal disease within previous 3 month randomization capable modify intestinal absorption drug ; severe pathology cancer , mental illness , etc. , opinion investigator might pose risk patient confound result study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Hypertriglyceridaemia</keyword>
	<keyword>Metabolic Syndrome</keyword>
</DOC>